Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Vyzulta latanoprostene bunod Open-angle glaucoma or ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Wainua eplontersen Polyneuropathy in hereditary transthyretin-mediated amyloidosis Active
Wakix pitolisant hydrochloride Narcolepsy Do not reimburse Complete
Waymade-Trientine trientine hydrochloride Wilson's Disease Reimburse with clinical criteria and/or conditions Complete
Wegovy semaglutide Weight management Do not reimburse Complete
Wegovy semaglutide Reduce the risk of major adverse cardiovascular events Pending
Welireg belzutifan von Hippel-Lindau disease-associated tumours Reimburse with clinical criteria and/or conditions Complete
Winlevi clascoterone Acne vulgaris Withdrawn
Winlevi clascoterone Acne vulgaris Active
Winrevair sotatercept Pulmonary arterial hypertension (WHO group 1) Active
Xalkori Crizotinib ROS1-positive advanced non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Xalkori Crizotinib Advanced Non-Small Cell Lung Cancer Do not reimburse Complete
Xalkori Crizotinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Xalkori Crizotinib First Line ALK Positive Advanced NSCLC Reimburse with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban (granules for oral suspension) Venous Thromboembolic Events Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Xarelto Rivaroxaban Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. Reimburse with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Venous thromboembolism, prevention N/A Complete
Xarelto Rivaroxaban Atrial fibrillation, stroke prevention List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Thromboembolism (venous), prevention List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism Complete
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Venous thromboembolic events, pulmonary embolism List with criteria/condition Complete
Xcopri cenobamate Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete